[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pre-diabetic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pre-diabetic":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,95,119,149,169,203],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100639897","prediabetes-glycemic-impact-and-data-evaluation-100639897",false,"NCT07599072","PREdiabetes GLycemic Impact and Data Evaluation","Evaluation of the Impact of Continuous Glucose Monitoring (CGM) Systems on Glycemic Control in People With Prediabetes: Postmarketing Clinical Study","PRE-GLIDE","Inclusion Criteria:\n\n* Age of 18 years and older.\n* Presence of prediabetes diagnosed according to criteria of the American Diabetes Association\n* Persons who treated with diet and exercise alone or metformin on a stabilized dose for at least 3 months before the study;\n* Ability to comply with protocol requirements and maintain a patient diary.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Presence of type 1 or type 2 diabetes;\n* Decompensated liver or kidney diseases (GFR \\\u003C 45 ml\u002Fmin\u002F1. 73 m²);\n* Active cardiovascular diseases within 12 months of Visit 1, such as myocardial infarction, clinically significant arrhythmia, unstable angina, coronary artery bypass surgery, or angioplasty; or are expected to require coronary artery bypass surgery or angioplasty during the course of the study;\n* Endocrine disorders (e.g., Itsenko-Cushing syndrome, acromegaly) that affect glycemia;\n* Pregnancy or lactation;\n* Mental or cognitive impairments that would interfere with study participation;\n* Daily use of any form of steroid medication (oral, inhaled, injected) within the last 3 months;\n* Recent use of any CGM within the last 12 months;\n* Known allergy to sensor materials;\n* Has evidence of current abuse of drugs or alcohol or a history of abuse that, in the investigator's opinion, would cause the individual to be noncompliant;\n* Participation in another clinical study within the last 3 months.","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective, randomized controlled trial evaluates whether real-time continuous glucose monitoring (CGM) improves glycemic control and lifestyle adherence in adults with prediabetes compared to conventional self-monitoring methods over a 3-month period. By analyzing metabolic markers and behavioral data, the study aims to determine the effectiveness of 24-hour monitoring as a personalized tool that increases patient adherence to lifestyle changes compared to conventional SMBG methods.",[27,28,29],"Pre Diabetic","Obesity & Overweight","Insulin Resistance",[31,32,33,34,35],"prediabetes","obesity","continuous glucose monitoring","insulin resistance","traditional glycemia self-monitoring","RECRUITING","2026-06-29",{"date":39,"type":40},"2026-06-30","ACTUAL",{"date":42,"type":21},"2026-07-01",{"date":44,"type":21},"2027-06-30",{"name":46,"class":47},"Nazarii Kobyliak","OTHER",3,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":73,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100605783","the-groceries-aimed-at-increasing-nutrition-study-100605783","NCT07167004","The GRoceries Aimed at Increasing Nutrition Study","Prompting a Switch From Refined Grains to Whole Grains in an Online Grocery Store Using Marketing Nudges and Financial Incentives","GRAINS","Inclusion Criteria:\n\n* Age 45 - 70 years.\n* Able to provide consent.\n* Resident of Philadelphia, Bucks, Delaware, Chester, or Montgomery Counties in Pennsylvania.\n* Consume \\\u003C5 servings of whole grains per week.\n* Use online grocery shopping at least once per month.\n* Have access to a credit or debit card to pay for groceries purchased.\n* Have reliable internet access.\n* Speak English.\n* Penn Medicine patient diagnosed with prediabetes or diabetes (identified using ICD-10 codes R73.03, E11).\n\nExclusion Criteria:\n\n* Does not meet all the inclusion criteria.\n* Not able to speak English.\n* Not able to provide consent.","45 Years","70 Years",{"count":60,"type":21},216,[24],"Only 2% of Americans meet the recommended levels of whole grain consumption, despite its association with reduced risk of type 2 diabetes. This study aims to assess if consumers with prediabetes or type 2 diabetes can be encouraged to switch from buying refined grain products to whole grain products when shopping for groceries online. The study will use personalized marketing strategies, with or without discounts which adjust based on purchasing behavior, to promote whole grain consumption.",[64,65,66,67,68,69,70,71,72],"Type 2 Diabetes","Type II Diabetes Mellitus","Type II Diabetes","Pre-diabetes","Pre-diabetic","Pre-diabetic State","Type 2 Diabetes Mellitus (T2DM)","Type 2 Diabetes Mellitus","Type 2 Diabetes (T2DM)",[74,75,76,77,78,79,31,80,81,82,83,84],"chronic disease","diabetes","diabetes mellitus","type II diabetes","type 2 diabetes","pre-diabetes","whole grains","behavioral economics","marketing nudges","financial incentives","food is medicine","2026-05-15",{"date":87,"type":40},"2026-05-19",{"date":89,"type":40},"2025-10-14",{"date":91,"type":21},"2027-02-16",{"name":93,"class":47},"University of Pennsylvania",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":108,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":48},"100625471","the-impact-of-continuous-glucose-monitoring-on-glucose-variability-and-weight-loss-in-individuals-with-prediabetes-and-obesity-100625471","NCT07423065","The Impact of Continuous Glucose Monitoring on Glucose Variability and Weight Loss in Individuals With Prediabetes and Obesity","The Impact of Continuous Glucose Monitoring on Behavioral Change, Glucose Variability and Weight Loss in Individuals With Prediabetes and Obesity - a Randomized Crossover Study","CGM","Inclusion Criteria:\n\n* Adults aged 18-70 years.\n* BMI ≥ 27 kg\u002Fm² (overweight or obese).\n* Prediabetes, confirmed by:\n\nImpaired fasting glucose (IFG: 5.6-6.9 mmol\u002FL), and\u002For Impaired glucose tolerance (IGT: 2-hour OGTT glucose 7.8-11.0 mmol\u002FL).\n\n* Stable body weight (±3 kg) in the last 3 months.\n* No current use of antidiabetic or weight-loss medications.\n* Willingness and ability to wear a CGM device as instructed.\n* Capacity to provide written informed consent.\n* Recruitment from the Diabetes Outpatient Clinic, Community Health Center Koper (identified and invited from the clinic's database).\n\nExclusion Criteria:\n\n* Diagnosis of type 1 or type 2 diabetes mellitus (fasting glucose ≥ 7.0 mmol\u002FL or HbA1c ≥ 6.5%).\n* Current or recent (within 3 months) use of:\n* Any antidiabetic medication (insulin, metformin, GLP-1RA, SGLT2i, etc.), or anti-obesity pharmacotherapy.\n* Pregnancy, breastfeeding, or planned pregnancy during the study period.\n* Severe chronic disease that could influence glucose metabolism or study participation (e.g., chronic liver disease, renal failure, active malignancy).\n* Endocrine disorders affecting metabolism (e.g., untreated thyroid disease, Cushing's syndrome).\n* Severe psychiatric illness or cognitive impairment limiting adherence or comprehension.\n* Use of medications known to affect glucose metabolism (e.g., corticosteroids, atypical antipsychotics).\n* Implanted electronic medical devices (e.g., pacemaker, defibrillator) that may interfere with CGM function.\n* Known allergy or skin reaction to CGM adhesives or device materials.\n* Participation in another interventional study within the previous 3 months.",{"count":104,"type":21},34,[24],"This randomized, crossover interventional study evaluates the effects of real-time (open) versus blinded continuous glucose monitoring (CGM) on glycemic variability, lifestyle behaviors, and metabolic outcomes in adults with prediabetes and overweight or obesity (BMI ≥ 27 kg\u002Fm²). Thirty participants will undergo both open and blinded CGM phases, separated by a washout period. The study aims to assess whether access to real-time glucose data promotes behavioral change and improves metabolic health compared with blinded CGM use.",[27,28],[33,32,31,109],"behavior","2026-04-27",{"date":112,"type":40},"2026-04-28",{"date":114,"type":21},"2026-09-01",{"date":116,"type":21},"2027-09-01",{"name":118,"class":47},"University of Primorska",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":101,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":148},"100634698","diabetes-prevention-by-group-intervention-and-cgm-use-in-pre-diabetic-adults-100634698","NCT07543068","Diabetes Prevention by Group Intervention and CGM Use in Pre-diabetic Adults","Inclusion Criteria:\n\n* Diagnosed with Prediabetes by a physician based on A1c, fasting glucose or American Diabetes Association (ADA) Type 2 risk test.\n* 18 to 75 years old inclusive.\n\nExclusion Criteria:\n\n* Non-English-Speaking individuals.\n* Diagnosed with Diabetes.\n* Use of glucose lowering medications (GLP-1, Metformin, etc.)\n* Pregnant women.\n* Unwilling to use Continuous Glucose Monitors (CGMs)\n* Unable to assist to the Group meetings in Conroe, TX.","75 Years",{"count":127,"type":21},20,[24],"This study is being done to find better ways to help people with prediabetes prevent or delay the development of type 2 diabetes. Prediabetes means your blood sugar is higher than normal, but not high enough to be diagnosed with diabetes. It is often silent, but without changes in diet and activity, many people progress to a diagnosis of diabetes within a few years.\n\nThe study combines two strategies:\n\n1. Group visits - small, regular meetings where patients learn about healthy eating, physical activity, and stress management.\n2. Continuous Glucose Monitors (CGMs) - small wearable sensors that measure blood sugar all day and show how food, movement, and sleep affect it in real time.\n\nBy bringing these two tools together, the research hopes to help participants better understand their own bodies and make lasting lifestyle changes.\n\nWhat is the purpose of this research?\n\nThe purpose of this research is to find out whether using a CGM device together with group sessions can help people with prediabetes lower their average blood sugar (measured by A1C) and improve confidence in managing their health.",[27,131],"Hyperglycaemia (Non Diabetic)",[101,133,134,135,136,137],"Pre Diabetes","Elevated sugar","Hyperglycemia","Hyperglycaemia","Interventions","NOT_YET_RECRUITING","2026-04-15",{"date":141,"type":40},"2026-04-21",{"date":143,"type":21},"2026-04",{"date":145,"type":21},"2026-12",{"name":147,"class":47},"Sam Houston State University",2,{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":167,"locationsCount":94},"100624373","effects-of-intermittent-fasting-variations-on-metabolic-inflammatory-and-nutrigenomic-profiles-in-prediabetes-a-randomized-controlled-trial-100624373","NCT07408791","Effects of Intermittent Fasting Variations on Metabolic, Inflammatory, and Nutrigenomic Profiles in Prediabetes: A Randomized Controlled Trial","The Effect of Intermittent Fasting Variations on Nutrigenomic Profile, Changes in Metabolic and Inflammatory Parameters, and Body Composition in Patients With Prediabetes","Inclusion Criteria:\n\n1. Patients with prediabetes, defined according to ADA criteria (fasting plasma glucose 100-125 mg\u002FdL or 2-hour postprandial glucose 140-199 mg\u002FdL).\n2. Willing to follow the fasting\u002Fdiet intervention protocol for 4-6 weeks (depending on the study duration).\n3. Signing informed consent and willing to be randomized into one of 3 intervention groups (Monday-Thursday Fasting\u002F5:2, Alternate-Day Fasting\u002FADF, or Time-Restricted Fasting\u002FIF).\n\nExclusion Criteria\n\n1. Diagnosis of type 2 diabetes mellitus.\n2. Currently undergoing antidiabetic drug therapy (e.g., metformin, sulfonylurea, insulin).\n3. Has a severe chronic disease (kidney failure, liver failure, heart failure, or eating disorder).\n4. Pregnancy or breastfeeding.\n5. History of eating disorders (anorexia nervosa, bulimia nervosa, or binge eating disorder).\n6. Taking medications that affect glucose metabolism (e.g., systemic steroids, atypical antipsychotics, etc.). Diagnosis of type 2 diabetes",{"count":157,"type":21},120,[24],"Prediabetes is a metabolic condition associated with increased risk of type 2 diabetes and cardiovascular disease. Intermittent fasting (IF) has emerged as a potential dietary intervention to improve metabolic health, yet comparative evidence among different IF patterns remains limited.\n\nThis randomized controlled trial aims to evaluate the effects of three intermittent fasting regimens-5:2 fasting, alternate-day fasting, and time-restricted feeding-compared with a control diet on metabolic parameters, inflammatory markers, body composition, and nutrigenomic profiles in adults with prediabetes.",[27],"2026-02-06",{"date":163,"type":40},"2026-02-13",{"date":165,"type":21},"2026-02",{"date":39,"type":21},{"name":168,"class":47},"DINA KEUMALA SARI",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":176,"sex":17,"minAge":177,"maxAge":125,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":148},"100587073","targeted-precision-nutrition-strategy-to-prevent-chronic-metabolic-diseases-100587073","NCT06923644","Targeted Precision Nutrition Strategy To Prevent Chronic Metabolic Diseases","PRECINUT","Inclusion Criteria:\n\n* Men and women with a BMI ≥25 to \\\u003C40 kg\u002Fm2\n* Classification possible to one of the investigational metabolic phenotypes according to the classification algorithm.\n* Weight stability for at least 3 months (+\u002F- 3 kg)\n\nExclusion Criteria:\n\nDiseases\n\n* (Pre-)diagnosis of type 1 or type 2 diabetes mellitus (i.e., FPG ≥ 7,0 mmol\u002FL) and HbA1c ≥ 6,5% (48 mmol\u002Fmol)\n* Renal or hepatic malfunctioning (pre-diagnosis or determined based on ALAT and creatinine values)\n* Gastrointestinal diseases or abdominal surgery (allowed i.e.:\n\nappendectomy, cholecystectomy)\n\n* Food allergies, intolerances (including gluten\u002Flactose intolerance) and\u002For eating disorders interfering with the study\n* Cardiovascular diseases (e.g., heart failure) or cancer (e.g., noninvasive skin cancer allowed)\n* High systolic blood pressure (untreated \\>160\u002F100 mmHg, drug-regulated \\>140\u002F90 mmHg)\n* Diseases affecting glucose and\u002For lipid metabolism (e.g., pheochromocytoma, Cushing's syndrome, acromegaly)\n* Diseases with a life expectation shorter than 5 years\n* Major mental disorders\n* Drug treated thyroid diseases (well substituted hypothyroidism is allowed inclusion)\n* Other physical\u002Fmental conditions that may interfere with study outcomes\n\nMedication\n\n* Medication known to interfere with study outcomes (e.g., PPAR-α or PPAR-γ agonists (fibrates), sulfonylureas, biguanides, α-glucosidaseinhibitors, thiazolidinediones, repaglinide, nateglinide, insulin, and chronic use of NSAIDs)\n* Use of certain anticoagulants other than acetylsalicylic acid\n* Use of antidepressants (stable use ≥ 3 months prior to and during study allowed)\n* Use of statins (stable use ≥ 3 months prior to and during study allowed)\n* Chronic corticosteroids treatment (\\>7 consecutive days of treatment)\n* Use of antibiotics within 3 months prior to the study\n\nLifestyle\n\n* Participation in regular sports activities (moderate-to-vigorous physical exercise \\>4 hours per week)\n* Having a restricted dietary pattern interfering with the study diets (e.g., vegetarian, vegan, Atkins diet and\u002For other special diets)\n* Plans to lose or gain more than 5% body weight\n* Abuse of alcohol (alcohol consumption \\>14 units\u002Fweek) and\u002For drugs (cannabis included)\n* Not willing to limit alcohol consumption to 7 drinks per week\n* Regular smoking (including use of e-cigarettes and vapes)\n* Use of strong vitamins or other dietary supplements (e.g., pre- or probiotics) expected to interfere with the study outcomes\n\nOther\n\n* Metabotype classification is not possible\n* Pregnant or lactating women, or women who are planning to become pregnant\n* Inability to comply with the study diet\n* Blood donation within the last 3 months\n* Participation in possibly interfering studies within the last 3 months\n* Inability to understand study information and\u002For communicate with staff\n* Unwillingness to be randomised or sign informed consent\n* Unwillingness to save data for 15 years\n* Deemed unsuitable for participation in the trial, for any reason, as judged by the research physician or principal investigator",true,"40 Years",{"count":179,"type":21},240,[24],"Nutrition is very important to keep blood sugar levels balanced. If blood sugar levels are too high, it can lead to diseases such as cardiovascular disease and type 2 diabetes (T2DM). Therefore, adjusting what one eats, also called a diet or nutritional intervention, can help prevent these diseases. However, not everyone responds the same to a diet. In about 30% of people, a diet does not work as hoped. This can be due to various reasons, such as a person's metabolism, genetic predisposition, the composition of the food one eats, or the bacteria in the intestines. Everyday things like sleep, stress, and movement also play a role. The investigators used a computer model to classify people with overweight and obesity into groups based on these factors. The investigators call such a group a 'Metabolic Phenotype', or in short 'Metabotype'. Based on the Metabotype, a personalised diet was developed (personalised nutrition intervention) that may better suit each person's unique situation.\n\nThe investigators hypothesize that a precision nutrition intervention, tailored to Metabotypes identified through unsupervised clustering (using the aforementioned computer model) of predefined, accurate features related to cardiometabolic health-specifically, tissue-specific glucose and lipid metabolism and detailed body composition-will enhance blood glucose homeostasis, reduce cardiometabolic risk, and improve adherence to the intervention and mental well-being, compared to population-based dietary guidelines. The present project will contribute to targeted and efficient precision-based dietary strategies for individuals at increased risk of T2DM.",[183,68,70],"Obesity and Overweight",[185,186,187,188,189,190,191,192,193],"Dietary intervention trial","Precision nutrition","Tissue-specific insulin resistance","Body composition","Metabotyping","Glucose homeostasis","Cardiometabolic health","Insulin resistance","Metabolic phenotype","2026-01-15",{"date":196,"type":40},"2026-01-20",{"date":198,"type":40},"2025-04-23",{"date":200,"type":21},"2027-04",{"name":202,"class":47},"Maastricht University Medical Center",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":210,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":214,"phases":4,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":94},"100614559","xinqiao-high-risk-cohort-of-diabetesnice-100614559","NCT07281170","Xinqiao High-risk Cohort of Diabetes(NICE)","Xinqiao High-risk Cohort of Diabetes","Inclusion Criteria:\n\n* Individuals who provide written informed consen\n* Have access to a smartphone\n* Hamily history of diabetes or abnormal microglucose level detected once\n* Age ≥18 years at the time of consent\n\nExclusion Criteria:\n\n* Diabetes mellitus\n* Any other condition which, in the judgment of the investigator, would make the subject unsuitable for enrollment in the study\n* recently surgical histories, trauma, acute cardiovascular complications, or infectious diseases","20 Months","79 Years",{"count":213,"type":21},7000,"OBSERVATIONAL","Objective: 1. To systematically screen the high-risk population of diabetes in Xinqiao area, understand the characteristics of early glucose metabolism changes and pancreatic islet function changes in the high-risk population and patients with prediabetes, and establish the first standardized research cohort of high-risk patients and prediabetes patients in Songjiang area.\n\n2\\. Use CGM monitoring technology to identify the high-risk groups of diabetes and the fluctuation of blood glucose in pre-diabetes, understand their ophthalmology and bone density, observe the annual conversion rate of diabetes, find effective interventions, move forward the management of diabetes, and create a new model for the management of high-risk groups of diabetes.\n\nResearch content: Part I: Establishing the first standardized diabetes high-risk population research cohort in Songjiang area The initiative focuses on early screening for high-risk populations with diabetes, shifting the focus downward and advancing prevention measures to detect diabetes at an earlier stage and initiate timely intervention. In Xinqiao District, all high-risk screening cases will undergo medical history documentation, anthropometric measurements, laboratory testing, and regular follow-ups. Standard oral glucose tolerance test (OGTT) methods will be employed to assess fasting blood glucose levels, insulin sensitivity, 2-hour postprandial glucose and insulin levels after a 75g glucose load, and glycated hemoglobin levels. Beyond evaluating glucose metabolism, the screening will also detect other metabolic disorders through routine blood tests including urinalysis, liver\u002Fkidney function tests, uric acid levels, lipid profiles, thyroid function, and urine protein\u002Fcreatinine ratio. The establishment of this premium high-risk screening program in Xinqiao Community will create Songjiang District's first standardized research cohort for diabetes mellitus (DM) and prediabetes patients, carrying significant strategic importance.\n\nPart II: By integrating Clinical Monitoring (CGM) technology with ophthalmological evaluations and bone density ultrasound examinations, we identify characteristics of high-risk diabetic populations and track their disease progression. The CGM system (with auxiliary devices such as the Shansheng Dynamic Glucose Monitoring System) is utilized to monitor blood glucose fluctuations in these individuals. Concurrently, comprehensive ophthalmic assessments-including visual acuity tests, intraocular pressure measurements, fundus photography, OCT scans, OCTA imaging, and SLO examinations-are conducted alongside bone density testing. Annual follow-up evaluations are performed to track clinical outcomes.\n\nResearch innovation points and expected results: Research innovation points:\n\nEstablish the first standardized research cohort of high-risk and pre-diabetic patients in Songjiang area; move forward the management of diabetes, and create a new management model for high-risk groups of diabetes.\n\nanticipated results\n\n1. Establish a new standardized diabetes high-risk population research cohort with large sample size.\n2. Observe the metabolic characteristics, blood glucose fluctuation, ophthalmic conditions and bone density of high-risk groups with diabetes.\n3. Find effective interventions to reduce the annual conversion rate of diabetes.",[27],[218,27,219],"xinqiao","NICE","2025-12-01",{"date":222,"type":40},"2025-12-15",{"date":224,"type":40},"2019-10-08",{"date":226,"type":21},"2034-12-31",{"name":228,"class":47},"Shanghai General Hospital, China"]